PATENT CLAIM ANALYSIS

Application Number: 16090142
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-04
Patent Classification: ["514", "250000"]

Abstract:
The invention provides methods for the prophylaxis or treatment of one or more disorders associated with dementia comprising administering to a patient in need thereof, a therapeutically effective amount of (i) a 5-HT2A or 5-HT2A/D2 receptor ligand and (ii) a PDE1 inhibitor, and pharmaceutical compositions comprising (i) a 5-HT2A or 5-HT2A/D2 receptor ligand and (ii) a PDE1 inhibitor.

Claim (Index 18):
The pharmaceutical composition of  claim 16  wherein the PDE1 inhibitor is a compound according to Formula II wherein R 2  is H and R 3  and R 4  together form a tri- or tetra-methylene bridge; or R 2  and R 3  are each methyl and R 4  is H; or R 2  and R 4  are H and R 3  is isopropyl; R 6  is optionally halo-subsitututed phenylamino or optionally halo-subsitututed benzylamino; R 10  is optionally halo-subsitututed phenyl, optionally halo-subsitututed pyridyl, or thiadiazolyl; in free or pharmaceutically acceptable salt form.

Metadata:
- Claim Count in Document: 68.0
- Percentile: 97.0
- Lexical Diversity: 1.64286
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14399334', '15977166', '14885813', '14066987', '14409866']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7949340163215436
- 35 USC 102 Novelty (BERT): 0.5023547242915489
- Combined Prediction Score: 0.7656760871185442
- Mean Citation Score: 271.499892
- Max Citation Score: 273.0258
- Similarity Product: 217.93318366588355

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test